Proponents of an emerging allergy treatment say they can help children by gradually exposing them to the very food they’re allergic to — but the treatment is not without risks.
An advisory panel to the FDA is expected to vote Friday on whether to recommend for approval AR-101, a kind of medical grade peanut flour produced by drug maker Aimmune Therapeutics.
Alex Smith from member station KCUR reports.
This article was originally published on WBUR.org.
Copyright 2021 NPR. To see more, visit https://www.npr.org. 9(MDExMDQwMzQzMDEzNjMyMTE3MjRkNzlmNg004))